A 42-year-old man experiencing nonischemic cardiomyopathy with severely reduced left ventricular function and advanced heart failure met the criteria for primary prophylactic implantation of an implantable cardioverter-defibrillator (ICD). A subcutaneous ICD (S-ICD; EMBLEM; Boston Scientific, Marlborough, MA) was implanted at a secondary center in November 2015 with the lead (3401; Boston Scientific) tunnelled in left parasternal position. Before implantation, surface ECG screening was performed following the manufacturer's instructions.
Case Report
A 42-year-old man experiencing nonischemic cardiomyopathy with severely reduced left ventricular function and advanced heart failure met the criteria for primary prophylactic implantation of an implantable cardioverter-defibrillator (ICD). A subcutaneous ICD (S-ICD; EMBLEM; Boston Scientific, Marlborough, MA) was implanted at a secondary center in November 2015 with the lead (3401; Boston Scientific) tunnelled in left parasternal position. Before implantation, surface ECG screening was performed following the manufacturer's instructions.
A few weeks later, the patient was transferred to Hannover Medical School because of heart failure deterioration (New York Heart Association class IV). After careful evaluation, a continuous-flow left ventricular assist device (LVAD; HeartMate 3; Thoratec, Pleasanton, CA) was implanted using conventional sternotomy. 1 Approximately 1 hour after LVAD implantation, the patient received 31 S-ICD shocks. The device was immediately deactivated. Interrogation of the S-ICD revealed normal sinus rhythm during the shocks. However, R waves were diminished and superimposed by electric noise caused by the LVAD. Oversensing of electromagnetic interference led to all S-ICD shocks ( Figure 1 ). Manually, all 3 sensing vectors, primary, secondary, and alternate at all available gain settings, were tested for adequate R wave sensing. In not a single configuration, the S-ICD was able to differentiate between R wave and T wave. Even flutter waves (F waves) were discriminated as R waves by the S-ICD ( Figure 2 ). Thus, after LVAD implantation, S-ICD therapy was not feasible any more.
Surface ECG screening was repeated after LVAD implantation. Both left and right parasternal electrode placement showed low R wave amplitudes and confirmed the inability of the S-ICD to differentiate between F, R, and T wave ( Figure 3 ).
After completion of rehabilitation period, the S-ICD was explanted and a conventional transvenous single-chamber ICD was implanted. During a follow-up of 6 months, the ICD showed a regular device function. Up to now, no oversensing or inappropriate therapy occurred.
Discussion
This case report illustrates inappropriate S-ICD shocks because of changes in R wave morphology and amplitude after LVAD implantation. Changes in ECG morphology after LVAD implantation have been described previously. 2 However, these consequences need special consideration when surface ECG-based systems like the S-ICD are used.
There are only few case reports dealing with the combination of S-ICD and LVAD therapy. One case describes successful combination of an LVAD (HeartMate II; Thoratec) and an S-ICD (SQ-RX pulse generator model 1010; Boston Scientific) without any electromagnetic interference. 3 Saeed et al 4 reported a case in which electromagnetic interference between the S-ICD and the LVAD (HVAD; HeartWare International, Inc, Framingham, MA) was observed. Two out of 3 sensing vectors showed electromagnetic interference after LVAD implantation. The electromagnetic noise was correctly classified by the S-ICD and did not lead to inappropriate shocks.
To our knowledge, this report describes the first case with inappropriate S-ICD shocks after LVAD implantation. The S-ICD shocks were caused by electromagnetic interference, changes in R wave morphology, and a decreased R wave amplitude after LVAD implantation.
Low voltage of R wave is commonly observed after LVAD implantation. 2 Because the device automatically adjusts its sensing threshold to the amplitude of the last sensed events, postoperative low voltage increases the risk of ventricular oversensing.
Conclusions
On the basis of our experience, we recommend deactivation of the antitachycardia therapy of the S-ICD before LVAD implantation. After recovery from surgery and before reactivation of the device, all sensing vectors should be evaluated with respect to adequate sensing and differentiation of R wave and T wave.
Because of sparse and inconsistent data about the combination of S-ICDs and LVADs, we recommend to avoid this combination until data have become more conclusive. 
